Harry L. Janssen
Expertise in
16
conditions

Harry L. Janssen

Erasmus MC
Rotterdam, ZH, NL 
Expertise in
16
conditions
Erasmus MC
Rotterdam, ZH, NL 

Overview

Harry Janssen practices practicing medicine in Rotterdam, Netherlands.

Mr. Janssen is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Hepatitis B, Hepatitis, Primary Biliary Cholangitis, Liver Transplant, and Mastectomy.

He is actively involved in clinical research, co-authoring 463 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Erasmus MC
Rotterdam, ZH, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

B-Fine: An Open Label, Single Arm Study to Mechanistically Interrogate the Therapeutic Effect of GSK3228836 in Patients With Chronic Hepatitis B Via Intrahepatic Immunophenotyping
B-Fine: An Open Label, Single Arm Study to Mechanistically Interrogate the Therapeutic Effect of GSK3228836 in Patients With Chronic Hepatitis B Via Intrahepatic Immunophenotyping
Enrollment Status: Completed
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: GSK3228836, Nucleos(t)ide therapy
Study Phase: Phase 2
Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment With GSK3228836 in Participants With Chronic Hepatitis B Virus (B-Clear)
Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment With GSK3228836 in Participants With Chronic Hepatitis B Virus (B-Clear)
Enrollment Status: Completed
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drugs: GSK3228836, Nucleos(t)ide therapy
Study Phase: Phase 2
View 1 Less Clinical Trial

463 Total Publications

Reply to "Role of HBV genotype, monitoring, and events after cessation of nucleos(t)ide analogue therapy".
Reply to "Role of HBV genotype, monitoring, and events after cessation of nucleos(t)ide analogue therapy".
Journal: Journal of hepatology
Published: June 26, 2026

Frequently Asked Questions about Harry L. Janssen

Is Harry L. Janssen a top-rated expert for Hepatitis B?

MediFind is an objective health platform that identifies experts based on real-world data. Harry L. Janssen is classified as an Elite expert for Hepatitis B, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Harry L. Janssen participate in research or clinical trials?

Yes. Harry L. Janssen has published 463 articles and abstracts on conditions like Hepatitis B. You can view a list of Harry L. Janssen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Janssen's expertise for a condition
ConditionClose
View All 8 Elite Conditions
View All 25 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile